As the COVID-19 pandemic continues, clinicians are learning more about the impact of the disease on the body, particularly in the lungs, and it’s shaping the way hospitals need to think about treating these patients – specifically with regard to what type of breath support to use.
In this episode in our Coronavirus Special Edition Series, Dr. Bill Croft, Ed.D, Ph.D., RRT, RCP, Executive Director of the North Carolina Respiratory Care Board, discusses the unique physiology of the COVID-19 lung, the pros and cons of BiPAP versus mechanical ventilators, and a more refined, incremental treatment path for breath support in COVID-19 patients.
For more on the use of invasive BiPAP as a potential alternative to mechanical ventilation, listen to our previous episode, Surviving the Ventilator Shortage. And to learn more about the Syneos Health Ventilator Initiative, visit www.COVID-biPAPinfo.com.
Stay tuned for more installments of the Coronavirus Special Edition Series, which explores, from an operational standpoint, the impact of COVID-19 on the biopharma industry, the challenges for rapid R&D in an outbreak environment, and the opportunities to leverage technology and innovation to address these critical issues. Additional materials and insights can also be found in our COVID-19 Resource Center.
If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision making and investment. You can find it all at insightshub.health.
Like what you’re hearing? Be sure to rate and review us!
We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at [email protected].
* This episode was recorded on 4/23/2020.